Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Chinese medtech company fined by UPC over injunction breaches

21 May 2026 The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.

Asia

Healthcare leads sweeping AI partnership in Singapore

20 May 2026 Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.

Americas

Jones Day adds in-house biologics specialist to Boston office

20 May 2026 The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.

More features

Patent office fee increases: What applicants must know

IndiaMart v CDSCO: A test of intermediary liability

Part I: Ozempic goes generic as Novo’s key patent expires

Emotional Perception: What next for patent holders?

Semaglutide patent battle heats up with new blow for Novo in India

Rooted in rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features